Table 2 Number of events, person-years and incidence rates for composite arterial and venous thrombotic events for first, second and booster vaccinationsa

From: Cohort study of cardiovascular safety of different COVID-19 vaccination doses among 46 million adults in England

Vaccination dose

Brand

Event

Events/100K person-years

Incidence rate

Dose 1

  

No vaccination

After first dose

No vaccination

After first dose

 

ChAdOx1

Arterial

75,655/205.00

73,330/ 95.63

369.05

766.83

Venous

21,230/205.00

17,525/ 96.09

103.56

182.39

BNT-162b2

Arterial

75,655/205.00

57,050/ 80.99

369.05

704.38

Venous

21,230/205.00

11,860/ 81.00

103.56

146.42

mRNA-1273

Arterial

75,655/205.00

255/ 5.11

369.05

49.89

Venous

21,230/205.00

190/ 5.10

103.56

37.25

Doses 1 and 2

  

After first dose

After second dose

After first dose

After second dose

 

ChAdOx1

Arterial

39,425/41.23

70,485/93.36

956.17

755.01

Venous

8685/41.27

16,120/93.60

210.46

172.22

BNT-162b2

Arterial

26,975/33.63

55,620/72.44

802.22

767.8

Venous

5260/33.67

11,400/72.69

156.22

156.83

mRNA-1273

Arterial

160/2.17

200/4.06

73.66

49.24

Venous

90/2.18

135/4.06

41.37

33.29

Booster

  

Primary course only

After booster vaccination

Primary course only

After booster vaccination

Primary course of ChAdOx1 or BNT-162b2 or mRNA-1273

BNT-162b2

Arterial

157,235/182.21

39,735/38.72

862.93

1026.14

Venous

32,545/182.54

7855/ 38.97

178.29

201.54

mRNA-1273

Arterial

157,235/182.22

3200/ 7.46

862.88

429.07

Venous

32,545/182.56

760/ 7.47

178.27

101.79

BNT-162b2 or mRNA-1273

Arterial

157,235/182.21

42,935/ 46.20

862.93

929.36

Venous

32,545/182.58

8615/ 46.37

178.25

185.79

Primary course of BNT-162b2 or mRNA-1273

BNT-162b2

Arterial

70,215/80.31

21,425/19.04

874.28

1125.34

Venous

13,830/80.45

3975/19.15

171.91

207.62

mRNA-1273

Arterial

70,215/80.29

870/ 2.23

874.52

389.78

Venous

13,830/80.45

185/ 2.24

171.91

82.76

BNT-162b2 or mRNA-1273

Arterial

22,300/21.25

874.73

1049.33

22,300/21.25

Venous

4165/21.39

171.88

194.72

4165/21.39

Primary course of ChAdOx1

BNT-162b2

Arterial

87,020/101.93

18,310/ 19.76

853.73

926.59

Venous

18,715/102.13

3880/ 19.81

183.25

195.83

mRNA-1273

Arterial

87,020/101.95

2325/ 5.21

853.59

446.61

Venous

18,715/102.12

575/ 5.24

183.27

109.82

BNT-162b2 or mRNA-1273

Arterial

87,020/101.95

20,635/ 24.94

853.54

827.32

Venous

18,715/102.08

4455/ 25.08

183.33

177.61

Primary course of BNT-162b2

BNT-162b2

Arterial

70,005/76.60

21,415/18.78

913.88

1140.44

Venous

13,700/76.75

3965/18.91

178.51

209.65

mRNA-1273

Arterial

70,005/76.59

860/ 2.02

914

426.6

Venous

13,700/76.80

180/ 2.04

178.38

88.15

BNT-162b2 or mRNA-1273

Arterial

70,005/76.59

22,275/20.79

913.99

1071.28

Venous

13,700/76.73

4145/20.96

178.54

197.8

  1. aAll counts rounded to the nearest 5 and counts less than 10 displayed as ‘10’. Bold formatting identifies headers within the table, specifically at each vaccination dose, to clearly delineate comparison groups.
Back to article page